Althea Massenburg, MD
Internal Medicine · Durham, NCNPI 1710924311
Payments from drug & device makers
Across 115 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$433
- Novo Nordisk$317
- Boehringer Ingelheim$144
- Dexcom, Inc.$114
- Astellas Pharma US Inc$101
- Pfizer$92
- plus $712 from 20 others
What the payments were for
- Food & beverage$1,912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $433 |
| Novo Nordisk | 19 | $317 |
| Boehringer Ingelheim | 7 | $144 |
| Dexcom, Inc. | 6 | $114 |
| Astellas Pharma US Inc | 6 | $101 |
| Pfizer | 6 | $92 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Amarin Pharma, Inc. | 4 | $65 |
| GSK | 4 | $62 |
| Merck | 5 | $61 |
| Amgen | 4 | $57 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Baxter Healthcare | 1 | $48 |
| Bayer | 2 | $47 |
| Insulet Corporation | 1 | $41 |
| Johnson & Johnson | 2 | $29 |
| AstraZeneca | 2 | $28 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Roche Diagnostics Corporation | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| Gilead | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,912 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $147,435 |
| JanuviaSitagliptin Phosphate | 73 | $63,441 |
| EliquisApixaban | 56 | $60,378 |
| MounjaroTirzepatide | 42 | $44,260 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 69 | $43,685 |
| JardianceEmpagliflozin | 38 | $32,748 |
| RybelsusSemaglutide | 26 | $29,377 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $14,010 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 43 | $13,824 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 55 | $12,217 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 33 | $10,722 |
| TrulicityDulaglutide | 11 | $10,327 |
| FarxigaDapagliflozin Propanediol | 11 | $8,545 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,774 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $317 | $176,812153 claims |
| MerckJanuvia, Janumet Xr | $61 | $107,126142 claims |
| PfizerEliquis, Abrysvo | $92 | $74,20399 claims |
| Lilly USA, LLCMounjaro, Trulicity | $433 | $54,58753 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $144 | $40,07550 claims |
| GSKShingrix, Arexvy, Breo Ellipta, Anoro Ellipta | $62 | $35,037111 claims |
| AstraZenecaFarxiga, Symbicort | $28 | $12,77828 claims |
| AbbVieSynthroid | $14 | $3,11734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Durham
- Manesh PatelDurham$27.2M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- April SalamaDurham$6.5M
- Hope UronisDurham$5M
- Richard RiedelDurham$2.6M
- Jamie ToddDurham$1.9M
- Nirmish ShahDurham$1.8M
- Aparna SwaminathanDurham$1.2M
- Cynthia MoylanDurham$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.